Omics Sciences



Facility manager

Annapaola Andolfo


The proteomics research area takes advantage from the most advanced mass spectrometry technologies to provide both accurate protein micro-characterization and large scale proteomics analyses in a large number of scientific projects and collaborations. A constant focus is kept on providing support in the interpretation of the results.

Research activity

Targeted quantitative proteomics: the facility developed a Parallel Reaction Monitoring (PRM) method for the specific quantification of myosin heavy and light chains in human heart biopsies with the aim of studying alterations associated with left ventricular hypertrophy in patients with cardiomyopathy. The PRM assay, performed in the high resolution and high mass accuracy mode on the Q-Exactive mass spectrometer, was crucial for the specific quantification of single isoforms with very high sequence homology (in collaboration with Dr Foglieni and Prof Camici, Myocardial diseases and atherosclerosis Unit, IRCCS Ospedale San Raffaele).

Label-free approach for discovery-based proteomics: the facility was involved in the definition of plasma membrane biomarkers in the context of hepatocarcinoma to discriminate different aetiologies such as HCV versus metabolic disorders and define patients' tailored therapy (in collaboration with Dr Siracusano and Dr Lopalco, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele).

Quantitative Post-Translational Modifications (PTM) analysis: Among the several PTMs, the ProMeFa laboratory has exploited a mass spectrometry method for the quantification of phosphorylation in Her2 receptor, in order to shed light in the trastuzumab molecular mechanism in the treatment of breast cancer (in collaboration with Dr Daniele and Prof Tacchetti, Experimental Imaging Center, IRCCS Ospedale San Raffaele).